Effectiveness of ixekizumab over 24 months in different clinical scenarios in psoriatic arthritis: results from the Gruppo Italiano Studio Early Arthritis multicentric prospective registry.

Autor:	Chimenti MS; Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, University of Rome Tor Vergata, Italy. maria.sole.chimenti@uniroma2.it., Fatica M; Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, University of Rome Tor Vergata, Italy., Fornaro M; Rheumatology Unit, DiMePRe-J, University of Bari, Italy., Lopalco G; Rheumatology Unit, DiMePRe-J, University of Bari, Italy., Corrado A; Rheumatology Unit, University of Foggia, Italy., Rotondo C; Rheumatology Unit, University of Foggia, Italy., Semeraro A; Rheumatology Unit, Valle d'Itria Hospital Martina Franca, ASL Taranto, Italy., Colella S; Rheumatology Unit, Valle d'Itria Hospital Martina Franca, ASL Taranto, Italy., Praino E; U.O.S. Reumatologia, DSS4 Barletta, ASL BT Andria, Italy., Gorla R; Rheumatology and Clinical Immunology Unit, ASST Spedali Civili of Brescia, Italy., Bazzani C; Rheumatology and Clinical Immunology Unit, ASST Spedali Civili of Brescia, Italy., Babaglioni G; Rheumatology and Clinical Immunology Unit, ASST Spedali Civili of Brescia, Italy., Foti R; Rheumatology Unit, A.O.U. Policlinico S. Marco, Catania, Italy., Floris A; Department of Medical Science and Public Health, University of Cagliari and Rheumatology Unit, Azienda Ospedaliero Universitaria di Cagliari, Monserrato, Italy., Frediani B; U.O.C. Reumatologia, Azienda Ospedaliero Universitaria Senese, Siena, Italy., Atzeni F; Rheumatology Unit, Department of Experimental and Internal Medicine, University of Messina, Italy., Conti F; Rheumatology Unit, Department of Clinical Internal, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Italy., Cauli A; Department of Medical Science and Public Health, University of Cagliari and Rheumatology Unit, Azienda Ospedaliero Universitaria di Cagliari, Monserrato, Italy., Caporali R; Dipartimento di Reumatologia e Scienze Mediche, ASST PINI-CTO and Dipartimento di Scienze Cliniche e di Comunità, Università di Milano, Italy., Iannone F; Rheumatology Unit, DiMePRe-J, University of Bari, Italy., Guiducci S; Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, Italy.
Jazyk:	angličtina
Zdroj:	Clinical and experimental rheumatology [Clin Exp Rheumatol] 2024 Jul 24. Date of Electronic Publication: 2024 Jul 24.
DOI:	10.55563/clinexprheumatol/udiit0
Abstrakt:	Objectives: We aimed to evaluate ixekizumab (IXE) effectiveness, drug survival and clinical response predictors in moderate-severe psoriatic arthritis (PsA) patients in different clinical scenarios. Methods: This was a multicentre real-life observational study based on Gruppo Italiano Studio Early Arthritis (GISEA) registry of IXE treatment in PsA patients (January 2019-June 2023). Data were collected at baseline and every six months. Results: 223 PsA outpatients were included. Statistically significant improvement was observed after 6 (T6), 12 (T12) and 24 (T24) months of therapy for tender and swollen joint count (TJC and SJC), Visual Analogue Scale (VAS)-pain and Disease Activity in PSoriatic Arthritis (DAPSA) score. DAPSA remission was reached at T12 in 22% and at T24 in 18.5% of patients. At baseline, higher fibromyalgia and combination therapy with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) in females with respect to males and higher Psoriasis Area Severity Index (PASI) in males than in females were observed. Therapeutic effectiveness showed in males higher DAPSA and VAS-pain reduction, higher percentage of males in DAPSA remission/low disease activity (LDA) at T6, and higher ∆PASI at T6 and T12 than in female patients. At multivariate analysis, male sex was predictive for treatment response at T6 [p=0.02, odds ratio (OR) 2.49 (95% confidence interval 1.11-5.54)], while it lost significance at T12. Conclusions: IXE effectiveness was highlighted after 6 months at both joint and skin levels and lasted up to 24 months in different clinical scenarios, making IXE effective in the complexity of managing PsA in a real-life setting.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu